I. Expression across cell types
Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| natural killer cell | 48 studies | 72% ± 24% | |
| plasmacytoid dendritic cell | 29 studies | 86% ± 14% | |
| CD8-positive, alpha-beta T cell | 26 studies | 43% ± 21% | |
| mature NK T cell | 18 studies | 67% ± 21% | |
| CD16-positive, CD56-dim natural killer cell, human | 17 studies | 82% ± 19% | |
| T cell | 15 studies | 33% ± 10% | |
| CD16-negative, CD56-bright natural killer cell, human | 15 studies | 55% ± 18% | |
| gamma-delta T cell | 15 studies | 46% ± 12% | |
| CD8-positive, alpha-beta memory T cell | 11 studies | 37% ± 11% | |
| effector memory CD8-positive, alpha-beta T cell | 8 studies | 39% ± 16% | |
| effector CD8-positive, alpha-beta T cell | 7 studies | 70% ± 15% | |
| effector memory CD8-positive, alpha-beta T cell, terminally differentiated | 5 studies | 57% ± 6% | |
| innate lymphoid cell | 5 studies | 41% ± 12% | |
| exhausted T cell | 4 studies | 39% ± 26% | |
| naive thymus-derived CD8-positive, alpha-beta T cell | 4 studies | 39% ± 26% | |
| mucosal invariant T cell | 3 studies | 22% ± 3% | |
| CD4-positive, alpha-beta T cell | 3 studies | 41% ± 17% | |
| CD4-positive, alpha-beta memory T cell | 3 studies | 27% ± 5% |
